ALESSANDRA GUARNACCIA

Dr. ALESSANDRA GUARNACCIA

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
GQGianluca Quaranta
Gianluca Quaranta
AGALESSANDRA GUARNACCIA
ALESSANDRA GUARNACCIA
GFGIOVANNI FANCELLO
GIOVANNI FANCELLO
CAChiara Agrillo
Chiara Agrillo
FIFederica Iannarelli
Federica Iannarelli
Luca MasucciLuca Masucci
Luca Masucci
The gut microbiota is composed of bacteria, archaea, phages, and protozoa. It is now well known that their mutual interactions and metabolism influence host organism pathophysiology. Over the years, there has been growing interest in the composition of the gut microbiota and intervention strategies in order to modulate it. Characterizing the gut microbial populations represents the first step to clarifying the impact on the health/illness equilibrium, and then developing potential tools suited for each clinical disorder. In this review, we discuss the current gut microbiota manipulation strategies available and their clinical applications in personalized medicine. Among them, FMT represents the most widely explored therapeutic tools as recent guidelines and standardization protocols, not only for intestinal disorders. On the other hand, the use of prebiotics and probiotics has evidence of encouraging findings on their safety, patient compliance, and inter-individual effectiveness. In recent years, avant-garde approaches have emerged, including engineered bacterial strains, phage therapy, and genome editing (CRISPR-Cas9), which require further investigation through clinical trials.

8 August 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
GQgianluca quaranta
gianluca quaranta
Gianluca IaniroGianluca Ianiro
Gianluca Ianiro
FMFlavio De Maio
Flavio De Maio
AGALESSANDRA GUARNACCIA
ALESSANDRA GUARNACCIA
GFGIOVANNI FANCELLO
GIOVANNI FANCELLO
Luca MasucciLuca Masucci
Luca Masucci
Fecal microbiota transplantation (FMT) consists of infusion of feces from a donor to a recipient patient in order to restore the resident microbial population. FMT has shown to be a valid clinical option for Clostridioides difficile infections (CDI). However, this approach shows several criticalities, such as the recruiting and screening of voluntary donors. Our aim was to evaluate the therapeutic efficacy of a synthetic bacterial suspension defined “Bacterial Consortium” (BC) infused in the colon of CDI patients. The suspension was composed by 13 microbial species isolated by culturomics protocols from healthy donors’ feces. The efficacy of the treatment was assessed both clinically and by metagenomics typing. Fecal samples of the recipient patients were collected before and after infusion. DNA samples obtained from feces at different time points (preinfusion, 7, 15, 30, and 90 days after infusion) were analyzed by next‐generation sequencing. Before infusion, patient 1 showed an intestinal microbiota dominated by the phylum Bacteroidetes. Seven days after the infusion, Bacteroidetes decreased, followed by an implementation of Firmicutes and Verrucomicrobia. Patient 2, before infusion, showed a strong abundance of Proteobacteria and a significant deficiency of Bacteroidetes and Verrucomicrobia. Seven days after infusion, Proteobacteria strongly decreased, while Bacteroidetes and Verrucomicrobia increased. Metagenomics data revealed an “awakening” by microbial species absent or low concentrated at time T0 and present after the infusion. In conclusion, the infusion of selected bacteria would act as a trigger factor for “bacterial repopulation” representing an innovative treatment in patients with Clostridioides difficile infections.

20 May 2022 in Current Microbiology
Verified
Journal Article
Closed access
PDF file
GQGianluca Quaranta
Gianluca Quaranta
JMJessica Mandrioli
Jessica Mandrioli
SBStefano Bibbò
Stefano Bibbò
AGALESSANDRA GUARNACCIA
ALESSANDRA GUARNACCIA
GFGiovanni Fancello
Giovanni Fancello
LMLuca Masucci
Luca Masucci

4 October 2023
Verified
Preprint
Open access
PDF file
AGALESSANDRA GUARNACCIA
ALESSANDRA GUARNACCIA
Dear authors, I have carefully reviewed the manuscript by San Nooij et al. “_Long-term beneficial effect of fecal microbiota transplantation on colonization of multidrug-resistant bacteria and resistome abundance in patients with recurrent Clostridi...